tofacitinib,upadacitinib,risankizumab,guselkumab,secukinumab,Ixekizumab,adalimumab
abbvie,pfizer,novartis,janssen,eli lilly
['tofa', 'upadacitinib', 'risan']
have newer targets made much more progress? yes. not as much as we wanted to, though!
acr20 outcome &gt; 50%
- future 1 / 2: secukin (il17)
- spirit: ixekiz (il17)
- opal: tofacit (jak)
- select-psa: upadacitinib (jak)
- discover: guselk (il23i)
-keepsake: risankiz
#acr22
(pronounced VUH-neet sun-dhoo) Mother. She/Her/Hers. Rheumatologist. Program Director @lluhealth. Tweets are not medical advice. #ACRAmbassador @lluhphysicians